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Disease activity and cognition in rheumatoid
arthritis: an open label pilot study
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John D Isaacs2,5
Abstract
Introduction: We hypothesised that fatigue in rheumatoid arthritis (RA) is related to TNF-alpha induced
dysregulation of cerebral blood flow. Our objectives were to assess fatigue, cognitive function and cerebral blood
flow before and after initiation of anti-TNF treatment.
Methods: In a pilot study, 15 patients initiating treatment with adalimumab were assessed for fatigue using a
visual analogue scale (FACIT-F), cognitive function using a panel of psychometric tests and regional cerebral blood
flow using MR perfusion imaging.
Results: Patients improved clinically after anti-TNF therapy in terms of DAS28 and FACIT-F. Furthermore significant
improvements were documented in full scale, verbal and performance IQ following therapy. There was a non-
significant trend towards reduced cerebral perfusion in both grey and white matter, and fatigue at 3 months
correlated with cerebral blood flow in white (p = 0.014) and grey (p = 0.005) matter.
Conclusions: We demonstrate for the first time a significant improvement in cognitive function following effective
treatment of RA. Although we observed minor reductions in cerebral blood flow, and a correlation between
cerebral blood flow and fatigue, a larger, controlled study would be required to affirm a causal relationship.
Introduction
Patients with rheumatoid arthritis (RA) report reduced
health-related quality of life, which is attributable to fati-
gue, pain and impairment of physical function. The fatigue
experienced is a pervasive symptom, which patients con-
sider highly important [1]. It is a different experience to
normal tiredness; patients frequently describe overwhelm-
ing exhaustion as well as cognitive fatigue, hindering clear
thought and concentration [2]. Effective treatment of RA,
particularly with biologic drugs, improves fatigue but it is
not clear if it also improves cognition [3]. While the
improvement in fatigue is assumed to be a direct conse-
quence of cytokine reduction, the physiological substrate
for such a profound effect is unclear.
TNF has been implicated in a number of neuropatholo-
gies [4]. A previous study into the effects of TNF on the
brains of Wistar rats found that a single intrastriatal
bolus of TNF led to significant reductions (15 to 30%) in
cerebral blood volume, which was dependent on TNF
type-2 receptor activation, and was preventable with an
endothelin receptor antagonist [5]. Neuroimaging studies
in RA have identified hypoperfusion of the frontal and
parietal lobes, while in systemic lupus erythematosus,
hypoperfusion of the frontal lobes has been associated
with cognitive dysfunction [6]. If TNF influences cerebral
blood flow (CBF) in humans, then the chronically high
levels associated with active RA may be implicated in
cognitive impairment. We therefore hypothesised that
treatment of active RA, particularly with TNF blockade,
would lead to improvements in both fatigue and cognitive
function, and that these effects would be related to changes
in CBF. A small pilot study was initiated to address this
possibility. Advances in magnetic resonance imaging (MRI)
technology and scanning techniques have allowed direct
and non-invasive imaging of CBF without the need for
contrast injection. We applied a CBF MRI technique in a
cohort of RA patients about to commence a TNF antago-
nist, and measured CBF, disease activity, fatigue and cogni-
tive function before and during treatment.
* Correspondence: grahamraftery@doctors.org.uk
1Department of Rheumatology, City Hospitals Sunderland NHS Trust, Kayll
Road, Sunderland, SR4 7TP, UK
Full list of author information is available at the end of the article
Raftery et al. Arthritis Research & Therapy 2012, 14:R263
http://arthritis-research.com/content/14/6/R263
© 2012 Raftery et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Materials and methods
This was an open-label pilot study. Cerebral MRI scans,
fatigue scores, 28-joint disease activity score (DAS28), and
psychometric assessment were performed on patients
before, and 12 weeks into, anti-TNF therapy for RA. Ethi-
cal approval was granted by Newcastle and North Tyne-
side 2 Research Ethics Committee. Funding was provided
by Abbott Laboratories. The funder was not involved with
study design, performance or data analysis.
Patients
Fifteen patients with RA according to 1987 American
College of Rheumatology (ACR) criteria were recruited.
Each had been identified as requiring anti-TNF therapy
as part of routine clinical care. Patients were excluded if
they had previously received any anti-TNF therapies or if
they had contra-indications to undergoing cerebral MRI.
Adalimumab 40 mg was administered by subcutaneous
injection every 2 weeks. The patients otherwise received
routine clinical care. The study was approved by the local
research ethics committee and all patients gave written,
informed consent.
MRI
Co-registered conventional MR images were acquired on a
Philips 3 Tesla scanner to define anatomy and show any
areas of focal abnormality (3-dimensional T1-weighted
sequence, TR/TE = 9.6/4.6 ms, 1 mm isotropic resolution;
T2-weighted sequence, TR/TE = 7079/100 ms, 1 mm
resolution, 3-mm slices). Slice orientation and the total
volume of tissue sampled were standardised across all sub-
jects. CBF imaging used a multi-slice pulsed arterial spin
labelling (ASL) sequence, flow-sensitive alternating inver-
sion recovery (FAIR) [7]. In-plane resolution was 4 mm
with 12 contiguous 6-mm-thick slices (TR was set to 4 s,
inflow time was set at 1.7 s and 40 image-pairs were col-
lected, 25 minutes total imaging time for perfusion and
associated T1 mapping data for absolute quantitation).
Slice angle and extent were controlled to match the slices
to the anatomical data.
Psychometric testing
All patients completed a set of neuropsychometric tests at
baseline and again after 12 weeks of treatment with adali-
mumab. The tests used were chosen to minimize any
learning effect and each session was administered by the
same trained researcher to avoid discrepancies in scoring.
The selected tests (see below) were considered those most
appropriate for patients with fatigue.
Assessment of global cognitive function: full-scale
intelligence quotient
The full-scale intelligence quotient (IQ) provides a sum-
mary of overall cognitive ability and was obtained using
a shortened version of the Wechsler Adult Intelligence
Scale III (WAIS-III), which assesses vocabulary compre-
hension, visuoconstructive ability (block design), verbal
reasoning (similarities) and nonverbal deductive reasoning
(matrices). Raw scores are compared with population age
and sex normative values, resulting in a T-score that is
standardised to a mean of 100 and SD of 15.
Assessment of specific cognitive deficits using the WAIS-III
Three subtests of the WAIS-III were used to obtain non-
standardised raw scores. The digit span test assesses
immediate recall for sequences of numbers increasing in
magnitude. The digit symbol search requires participants
to indicate whether one of two symbols is present in an
array; this depends on paired associate learning (the ability
to deal with two stimuli at once and to be able to associate
them). The patients also completed a trail-making test of
visual scanning, requiring a combination of information-
processing speed, manual motor speed, and sustained
attention.
Fatigue
Fatigue was measured using the functional assessment
of chronic illness therapy fatigue scale (FACIT), a sim-
ple-to-administer questionnaire, which has been vali-
dated in RA patients [8]. The range of possible scores is
0 to 52; greater scores reflect less fatigue.
MRI analysis
Perfusion images were processed into maps of quantita-
tive regional cerebral blood flow (rCBF) and corrected
for image distortion. The rCBF maps were analysed in
two ways: (1) analysis of rCBF in grey and white matter
was carried out to look for global differences between
patients in brain perfusion, and for changes with therapy.
The anatomical images were subjected to supervised tis-
sue classification to define gross regions of interest (ROI)
for white matter, grey matter, cerebro-spinal fluid (CSF),
deep grey structures and any focal abnormalities. These
ROIs were applied to the CBF dataset to determine aver-
age flow in each tissue type; (2) statistical analysis by
group was applied to look for any regional differences or
changes in perfusion. The Statistical Parametric Mapping
(SPM) software package (SPM 5) was used to transform
CBF data into a standardised brain space [9]. SPM was
then applied to calculate pixel-wise group statistics
between patients pre- and post-therapy to determine
areas of differences in rCBF, and to perform regression
analysis of clinical measures [10].
Statistical analysis
Statistical analysis was performed using SPSS (Version
15 - IBM Corporation, USA). Tests for normality were
performed using the Kolmogorov-Smirnov test. Interval
data were compared using Pearson’s correlation coeffi-
cient, and ordinal data were analysed using Spearman’s
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correlation coefficient. Cognitive function and CBF at
baseline and 12 weeks were compared using the paired
t-test. DAS28 scores and FACIT fatigue were compared
using the Wilcoxon signed-rank test. Possible predictors
of cognitive function were analysed as independent vari-
ables using a forced entry method of multiple regression
analysis. A P-value < 0.05 was considered statistically
significant.
Results
Fifteen patients were recruited and thirteen completed all
aspects of the study (Table 1). One patient inadvertently
commenced adalimumab prior to baseline MRI, and one
patient stopped anti-TNF therapy after 6 weeks and
declined further study participation. Analysis was based on
the paired datasets from the 13 patients completing the
study; 12 patients were female and one was male; the
mean age of the group was 48.92 (SD 8.04) years.
Clinical response
All participants had a high level of baseline disease activity
and fatigue (table 1). There were significant improvements
in DAS28 (P = 0.002) and FACIT F score (P = 0.002) with
adalimumab treatment. A significant relationship was
observed between age and baseline FACIT fatigue score
(P = 0.03), increasing age corresponding with lower levels
of fatigue, as well as between baseline DAS28 and baseline
FACIT fatigue score (P = 0.018) (higher DAS28 corre-
sponding with greater fatigue).
Cerebral imaging
There was no significant influence of adalimumab treat-
ment on either grey or white matter CBF (P = 0.183 and
P = 0.210 respectively, data not shown). SPM software
applied to calculate group statistics between patients pre-
and post-therapy did not identify any focal areas of statisti-
cally significant differences in rCBF.
FACIT fatigue score after 3 months of treatment corre-
lated with both grey (Correlation coefficient (r) = -0.724,
P = 0.005) and white (r = -0.660, P = 0.014) matter CBF at
3 months, lower CBF corresponding to less fatigue at
3 months (Figure 1).
Cognitive function
The mean full scale IQ prior to anti-TNF therapy was
103.8 (SD 10.6), which compares to an age- and sex-
adjusted population mean score of 100 (SD 15). Significant
improvements in cognitive function were associated with
anti-TNF therapy (Figure 2); raw and normalised scores
for full scale IQ, performance IQ, and verbal IQ improved
significantly after 12 weeks of treatment. Particularly
marked improvements were seen in performance IQ (raw
data P = 0.004, normalised data P = 0.002). Further analy-
sis to investigate potential correlates of IQ improvements
did not reveal any significant associations with FACIT fati-
gue, DAS28, or CBF.
Discussion
To our knowledge this is the first study to demonstrate an
improvement in cognitive function following effective
treatment of RA. Improvements in cognitive function
related particularly to performance IQ, but we did not
demonstrate a relationship with CBF, fatigue or disease
activity. The physiological correlate of improved cerebral
function therefore remains unexplained and requires
further study. Although improvements followed treatment
with anti-TNF therapy, the lack of a control group in this
small pilot study preclude any conclusions being drawn
Table 1 Patient demographic data, disease activity scores (DAS28), and fatigue scores (FACIT fatigue)
Patient
number
Age
(years)
Rheumatoid
factor status
Disease
duration
(years)
Concurrent
DMARD
Concurrent
corticosteroid
NSAID or COX2
DAS 28 pre-
adalimumab
DAS 28 after 3
months of
adalimumab
FACIT
fatigue pre-
adalimumab
FACIT fatigue
after 3 months
of adalimumab
1 49 + 13 leflunomide diclofenac 7.38 2.84 15 33
2 43 + 7 none celecoxib 7.42 3.88 2 46
3 57 - 14 Methotrexate
leflunomide
celecoxib 6.37 3.41 22 45
4 60 + 4 none celecoxib 6.32 2.59 46 44
5 44 - 9 none none 6.36 4.36 9 25
6 37 + 17 methotrexate naproxen 6.33 4.50 11 20
7 39 + 13 methotrexate diclofenac 6.56 3.53 17 43
8 39 - 18 methotrexate indomethacin 6.25 4.46 25 33
9 61 - 12 none none 6.01 2.16 26 47
10 52 - 12 sulfasalazine none 7.37 2.95 18 39
11 49 - 13 methotrexate none 6.29 5.41 16 36
12 53 + 10 leflunomide diclofenac 8.20 4.49 15 24
13 53 + 13 none none 5.11 5.11 40 41
COX2, Cyclooxygenase-2 inhibitor; DMARD, disease-modifying anti-rheumatic drug; NSAID, non-steroidal anti-inflammatory drug.
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regarding the specificity of the effect, and future studies
should incorporate additional treatment options.
There is a paucity of data on cognitive function in RA
populations. Appenzeller, et al. observed cognitive
impairment in 30.0% of RA patients and 7.5% of healthy
controls [11]. Patients with RA had worse outcomes in
verbal fluency, logical memory and short-term memory,
while those with active disease had worse cognition scores.
(a) (b)
P=0.005
P=0.014
Figure 1 Correlation between fatigue levels and cerebral flow after 12 weeks of treatment with adalimumab. (a) Grey matter (P = 0.005).
(b) White matter (P = 0.014). FACIT, functional assessment of chronic illness therapy fatigue scale.
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Figure 2 Cognitive function test changes between baseline and 12 weeks. (a) Full scale IQ. (b) Verbal IQ. (c) Performance IQ. Standardised
data presented. Pre, pre-treatment with adalimumab; post, post-treatment with adalimumab.
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A psychometric assessment of 30 patients with RA, which
related performance to neuroimaging, found an abnormal
prevalence of impaired cognitive performance, particularly
in attention tasks, planning abilities and cognitive flexibil-
ity, and identified deficits related to cortical function;
visual memory was impaired in 50% and verbal memory in
35% [12]. Abnormalities on MRI were found with white
matter hyperintensity in 35% of patients, all of whom had
low scores in attention, executive and visuospatial tests.
Fatigue is virtually ubiquitous in RA, part of which is a
cognitive fatigue with lack of clarity of thought and an
inability to concentrate [2]. It often improves with biologic
therapies, suggesting that aspects of fatigue are centrally
driven and mediated by TNF or interleukin-6 [3,13].
While pain and depression may underpin some of this
relationship, fatigue is present in as many as one third of
RA patients with low levels of disease activity and lack of
clinical depression [14]. Our work reaffirms that the rela-
tionship between fatigue, cognition and disease activity is
a complex one, and that some aspects are responsive to
therapy. The improvement in performance IQ suggests
that cognitive function alone needs to be carefully consid-
ered; it may be independent of fatigue or it may be a sub-
set of the symptom complex of fatigue, with the exciting
prospect that aspects of it are modifiable by treatment.
MRI did not reveal a physiological correlate of changes
in cognitive function, although fatigue at 3 months corre-
lated with CBF in white and grey matter. We applied a
pulsed ASL sequence technique (FAIR), which allowed a
noninvasive measurement of perfusion. This is the first
use of ASL in an RA cohort. Bartolini, et al. assessed per-
fusion with single-photon emission computed tomography
and found 85% of patients had hypoperfusion of the fron-
tal lobes, with parietal lobe hypoperfusion in 40%. Our
study was designed specifically to detect longitudinal
changes in CBF as a function of treatment, and so does
not allow cross-sectional quantitative assessment of base-
line regional perfusion differences. However, visual inspec-
tion of the CBF data did not reveal any obvious frontal
hypoperfusion in our group. Interestingly, lower CBF cor-
related with lower levels of fatigue at 3 months, alongside
a weak trend for a reduction in CBF after 3 months of
treatment with adalimumab. These data are counterintui-
tive; our hypothesis was that TNF blockade would
enhance CBF and this enhancement would correlate with
improvement in fatigue. However, we may have missed
any acute effects of treatment on CBF and would recom-
mend imaging soon after treatment initiation in future
studies. Nonetheless, the inverse correlation between fati-
gue and CBF at 3 months remains intriguing.
Conclusions
Our small pilot study has demonstrated an apparent
improvement in cognitive function with effective
treatment of RA. We could not link changes in CBF
with improved cognitive function despite a possible
influence on fatigue. Future studies need to address and
confirm the specificity of this treatment effect, as well as
seeking earlier treatment-related changes in CBF. The
major challenge is to build a template for cognition and
fatigue in RA, with a view to establishing a more com-
plete understanding of pathophysiological influences,
with the ultimate aim of identifying and directing effec-
tive treatment.
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